Building on post #7 rather than restating it. I would rather this thread reach "we do not know" about Reading SURMOUNT-1 without the press than reach a confident answer that nobody can support when asked.
Reading SURMOUNT-1 without the press release — one year on — setting out what I have, and where I think it stops being reliable.
I would like to disagree carefully with the settled view on Reading SURMOUNT-1 without the press, and I would like to be argued out of it if the disagreement is bad.
The disagreement is about one step, not about the conclusion. If the step holds I withdraw it entirely.
SURMOUNT-1 reported weight reduction of a magnitude that was the largest for a pharmacological intervention at that time of publication. It also reported a clear dose response across three doses. The categorical thresholds (people reaching 10%, 15%, 20% loss) got the most attention but read less informatively than the mean weight change.
That distinction has done more work for me than anything else in this category.
Bookmarking this. I will come back when I have something worth adding.
Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.
The apnoea-hypopnoea index used in SURMOUNT-OSA is an objective measurement rather than a symptom scale, which is why that trial carries more weight than its size suggests. Two parallel trials with and without positive airway pressure addressed the obvious confounder directly.
Gastrointestinal effects were comparable in character to the GLP-1 monoagonists across the programme. Individual reports here vary in both directions, which is what you would expect from a between-person difference rather than a between-drug one.
If that is already documented somewhere, ignore me and link it.
Building on post #7 rather than restating it.
I would rather this thread reach "we do not know" about Reading SURMOUNT-1 without the press than reach a confident answer that nobody can support when asked.
I had written a reply contradicting post #7 and deleted it. Here is what survived.
A request rather than an answer: could whoever has the primary source for Reading SURMOUNT-1 without the press post it? I have seen the claim three times this month and each version had lost a qualifier.
Confirming post #7 from a second method, which matters more than confirming it from a second person.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
The 2.5 mg starting dose is a tolerance step and not a therapeutic one. Judging efficacy at that dose is the single commonest reasoning error in this subcategory.
The honest answer is that it depends, and here is what it depends on.
What I would want before treating Reading SURMOUNT-1 without the press as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually missing.
SURMOUNT-OSA is notable because it used an objective physiological endpoint, the apnoea-hypopnoea index, rather than a symptom scale. Two parallel trials, with and without positive airway pressure, addressed the confounder directly. The reduction was substantial in both.
Worth separating two things that post #10 runs together.
Injection-site reactions were reported at a low but non-zero rate across the trials. The practical point is that a reaction at one site does not predict a reaction at the next, and rotating properly makes the question moot.
I would put moderate confidence on the mainstream reading of Reading SURMOUNT-1 without the press and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
Taking post #16 at face value and following it one step further.
On storage: published stability data covers the licensed formulation at its licensed concentration. A research preparation reconstituted at home in a different diluent at a different concentration is outside every one of those conditions.
Post #14 and I disagree about the size of the effect, not about the direction.
Comparisons between the tirzepatide and semaglutide programmes across trials rather than within one are weak. Different populations, different durations, different baseline characteristics; the only fair comparison is a head-to-head one.
The mechanism is plausible, which is not the same as established.
That is clearer than the version I had in my head. Thank you.
Where I part company with post #18, and it is a narrow parting.
Heart rate rises modestly across this class, tirzepatide included. It is consistent, small, and worth knowing about rather than worth alarm — and it is one of the reasons the trials monitored it explicitly.
Everything in post #20 holds. The case it does not cover is the one I have.
Weight reduction figures from SURMOUNT-1 are frequently quoted without the trial's duration attached. A mean change at 72 weeks and a mean change at 40 weeks are different numbers and both circulate.
I am aware this is the third time this month I have made this point.
The strongest argument against my own position on Reading SURMOUNT-1 without the press, stated as well as I can state it, since nobody else has yet.
Distinguishing three things in the Reading SURMOUNT-1 without the press discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
SURMOUNT-4 used a randomised withdrawal design: everyone titrated, then those on maintenance were randomised to continue or placebo. Continuation maintained effect; withdrawal was followed by regain. The finding is robust but it says nothing about a lower effective maintenance dose, because that was not studied.
This is the version I would want a new member to read first.
Answering the question post #23 raises rather than the one it answers.
Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.
The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.
Post #27 is the version of this I will quote in future. One addition.
Reading SURMOUNT-1 without the press would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
Heart rate rises modestly across this class, tirzepatide included. It is consistent, small, and worth knowing about rather than worth alarm — and it is one of the reasons the trials monitored it explicitly.
The apnoea-hypopnoea index used in SURMOUNT-OSA is an objective measurement rather than a symptom scale, which is why that trial carries more weight than its size suggests. Two parallel trials with and without positive airway pressure addressed the obvious confounder directly.
That matches what I was told, which is not the same as knowing it.